CervoMed reports Phase 2a biomarker data: neflamapimod reduces GFAP, correlates with clinical outcomes in DLB

CervoMed Inc.

In pure DLB patients, neflamapimod reduced GFAP by mean 10.6 pg/mL vs 14.1 increase with placebo (p=0.04).
GFAP reduction correlated with improvement on CDR-SB (r=0.542, p=0.036) in neflamapimod-treated pure DLB patients.
Preclinical data from UCL shows neflamapimod enhances axonal transport in tauopathy mouse model of FTD.
CEO states data support clinical efficacy in DLB and rationale for evaluating neflamapimod in frontotemporal dementia.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.